Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. From Wikipedia
The trial showed 15.7% average weight loss over 68 weeks, below expectations and earlier trial results, causing a significant drop in stock value.
